Memphis Pharmaceuticals results, Q2 2025
Net profit, assets, equity and cash flow for Q2 2025, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit127 millionEGP · +118.9% vs the same period a year earlier
Total assets1.34 billionEGP · +33.7% vs the same period a year earlier
Shareholders' equity382 millionEGP · +158.1% vs the same period a year earlier
Operating cash flow-29.02 millionEGP · −130.1% vs the same period a year earlier
In short
- Memphis Pharmaceuticals's net profit for Q2 2025 was about 127 million EGP, up +118.9% from 58.12 million EGP in Q2 2024.
- Total assets at the end of Q2 2025 were about 1.34 billion EGP, and shareholders' equity about 382 million EGP.
- Operating cash flow for Q2 2025 was negative at 29.02 million EGP.
Key lines against the same period a year earlier
This periodQ2 2024Change
Net profit127 million58.12 million+118.9%
Gross profit268 million103 million+159.7%
Total assets1.34 billion1 billion+33.7%
Total liabilities—856 million—
Shareholders' equity382 million148 million+158.1%
Total liabilities and equity1.34 billion1 billion+33.7%
Operating cash flow-29.02 million96.49 million−130.1%
Investing cash flow21.63 million8.86 million+144.1%
Financing cash flow-50.97 million133 million−138.3%
Net change in cash—238 million—
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Memphis Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy